CONMED Q2 adjusted EPS $1.38 beats; raises FY2026 adjusted EPS guidance to $4.48-$4.60

CONMED Corp

Q2 sales $343.5M (+0.3% as reported); organic constant currency sales +6.0% excluding GI product exits.
GAAP EPS $0.77 (+11.6%); adjusted EPS $1.38 (+20.0%), both include $0.21 IEEPA tariff refund benefit.
Full-year 2026 adjusted EPS guidance raised to $4.48-$4.60 (prior $4.30-$4.45); organic constant currency growth guidance narrowed to 5.0%-6.0%.
Appointed John E. Gallagher as CFO effective July 15, 2026; added Celine Martin and Jeff Mirviss to Board effective July 1.
AirSeal Robotic Solution now indicated for use with Intuitive's da Vinci 5 platform (8 mm hex cannulas).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.